|
|
|
市場調査レポート
革新的標的癌治療：主な技術、新たな適用、および主要企業
Innovative and Targeted Cancer Therapies: Key technologies, new applications and leading players
|
Abstract
The highly dynamic cancer market is creating a new age of discovery and
innovation driven by molecular biology, oncogenomics and new methods in cell
biology. Resultantly, cancer innovatives are not only the fastest growing
segment within the cancer market, but the key drivers of sales growth across
the pharmaceutical market as a whole. These innovations will result in high
value opportunities to develop newer and more effective therapies, ensuring
companies can effectively respond to the increasing prevalence of cancer.
Innovative and Targeted Cancer Therapies provides a detailed insight into both
cancer therapeutics and diagnostics, to provide a clear vision of how the
cancer market will develop over the next five years. It also identifies key
alliance and partnering opportunities, highlighting companies with specialised
capabilities in the discovery and the characterization of next-generation drug
targets. Use this report to understand how the cancer market is developing,
identify areas of unmet medical need and align your product pipeline to
achieve clinical and commercial success.
Table of Contents
Executive summary
- Cancer innovations are driving pharmaceutical industry growth
- Key innovations and technologies
- Key therapy areas and applications
- Key companies and pipelines
- Key trends and implications
Chapter 1 Cancer innovations driving pharma growth
- Summary
- Introduction
- Definitions
- Historical performance
- Impact of cancer market on industry as a whole
Chapter 2 Key innovations and technologies
- Summary
- Introduction
- Oncology treatment pathways
- Chemotherapeutics
- Hormonals
- Monoclonal antibodies
- Targeted therapies
- Immunotherapy and vaccines
- Leading marketed technologies
- Rituxan/ MabThera
- Herceptin
- Gleevec/ Glivec
- Avastin
- Eloxatin
- Erbitux
- Xeloda
- Femara
- Temodar
- Tarceva
- Leading new technologies for the future
- Kinase inhibitors
- Tubulin and microtubule inhibitors
- Topoisomerase inhibitors
- Cluster of differentiation receptor agonists
- DNA polymerase inhibitors
Chapter 3 Key therapy areas and applications
- Summary
- Introduction
- Key therapy areas
- Current treatment protocols and unmet needs
- Lung cancer
- Colorectal cancer
- Lymphomas
- Leukemia
- Breast cancer
- Likely future breakthroughs
- Alimta
- Gardasil
- Sutent
- Abraxane
- Nexavar
- Vectibix
- Sprycel
- Tykerb
- Cervarix
- MDX-010
Chapter 4 Key companies and pipelines
- Summary
- Introduction
- Leading players
- Leading oncology strategies
- Lifecycle management growth
- Diversification growth
- Novartis
- Pfizer
- Bristol-Myers Squibb
- Franchise development growth
- Sanofi-Aventis
- Schering-Plough
- Eli Lilly
- New market entry growth
- Merck
- Bayer Schering
- Amgen
- GlaxoSmithKline
Chapter 5 Key trends and implications
- Summary
- Introduction
- Future market growth
- Market opportunity
- Availability of effective treatments
- Leading technologies of tomorrow
- Key oncology success factors
- Lifecycle management
- New product development
- Index
List of Figures
- Figure 1.1: Global cancer innovatives market, 2003-2006
- Figure 1.2: Total pharmaceutical market and oncologics sales, 2004-2006
- Figure 1.3: Total oncologics and cancer innovatives sales, 2004-2006
- Figure 2.4: Leading cancer innovatives products, 2005-2006
- Figure 2.5: Rituxan/ MabThera (rituximab), 2003-2006
- Figure 2.6: Herceptin (trastuzumab), 2003-2006
- Figure 2.7: Gleevec/ Glivec (imatinib), 2003-2006
- Figure 2.8: Avastin (bevacizumab), 2003-2006
- Figure 2.9: Eloxatin (oxaliplatin), 2003-2006
- Figure 2.10: Erbitux (cetuximab), 2003-2006
- Figure 2.11: Xeloda (capecitabine), 2003-2006
- Figure 2.12: Femara (letrozole), 2003-2006
- Figure 2.13: Temodar (temozolomide), 2003-2006
- Figure 2.14: Tarceva (erlotinib), 2003-2006
- Figure 2.15: Cancer innovations by mode of action, 2007
- Figure 3.16: Cancer incidence in US, 2007
- Figure 3.17: Cancer deaths in US, 2007
- Figure 3.18: Cancer mortality rates in US, 2007
- Figure 3.19: New cancer deaths in US, 2007-2012
- Figure 3.20: Unmet needs in cancer markets across seven major markets, 2005
- Figure 3.21: Alimta (pemetrexed), 2004-2007
- Figure 3.22: Gardasil (human papillomavirus vaccine), 2006-2007
- Figure 3.23: Sutent (sunitinib), 2006-2007
- Figure 3.24: Abraxane (paclitaxel), 2005-2007
- Figure 3.25: Nexavar (sorafenib), 2006-2007
- Figure 3.26: Vectibix (panitumumab), 2006-2007
- Figure 3.27: Sprycel (dasatinib), 2006-2007
- Figure 4.28: Leading cancer innovatives companies, 2006-2007
- Figure 4.29: Genentech' s cancer innovatives, 2003-2006
- Figure 4.30: Roche' s cancer innovatives, 2003-2006
- Figure 4.31: Novartis' s cancer innovatives, 2003-2006
- Figure 4.32: Pfizer' s cancer innovatives, 2003-2006
- Figure 4.33: Bristol-Myers Squibb' s cancer innovatives, 2003-2006
- Figure 4.34: Sanofi-Aventis' s cancer innovatives, 2003-2006
- Figure 4.35: Schering-Plough' s cancer innovatives, 2003-2006
- Figure 4.36: Eli Lilly' s cancer innovatives, 2003-2006
- Figure 5.37: Cancer innovatives market forecast, 2003-2011
- Figure 5.38: New vs. established cancer innovatives market growth,
2003-2011
- Figure 5.39: Leading cancer innovatives drug classes, 2003-2011
- Figure 5.40: Leading cancer innovatives drugs, 2011
List of Tables
- Table 1.1: Global cancer innovatives market, 2003-2006
- Table 2.2: Leading cancer innovatives products, 2003-2006
- Table 2.3: Rituxan/ MabThera (rituximab) profile
- Table 2.4: Herceptin (trastuzumab) profile
- Table 2.5: Gleevec/ Glivec (imatinib) profile
- Table 2.6: Avastin (bevacizumab) profile
- Table 2.7: Eloxatin (oxaliplatin) profile
- Table 2.8: Erbitux (cetuximab) profile
- Table 2.9: Xeloda (capecitabine) profile
- Table 2.10: Femara (letrozole) profile
- Table 2.11: Temodar (temozolomide) profile
- Table 2.12: Tarceva (erlotinib) profile
- Table 3.13: Top 10 future breakthrough cancer innovatives
- Table 3.14: Future breakthrough cancer innovatives firsts...
- Table 3.15: Alimta (pemetrexed) profile
- Table 3.16: Gardasil (human papillomavirus vaccine) profile
- Table 3.17: Sutent (sunitinib) profile
- Table 3.18: Abraxane (paclitaxel) profile
- Table 3.19: Nexavar (sorafenib) profile
- Table 3.20: Vectibix (panitumumab) profile
- Table 3.21: Sprycel (dasatinib) profile
- Table 3.22: Tykerb (lapatinib) profile
- Table 3.23: Cervarix (human papillomavirus vaccine) profile
- Table 3.24: MDX-010 (ipilimumab) profile
- Table 4.25: Leading cancer innovatives companies, 2003-2006
- Table 4.26: Genentech' s cancer innovatives profile
- Table 4.27: Genentech' s cancer innovatives profile (continued)
- Table 4.28: Roche' s cancer innovatives profile
- Table 4.29: Roche' s cancer innovatives profile (continued)
- Table 4.30: Novartis' s cancer innovatives profile
- Table 4.31: Novartis' s cancer innovatives profile (continued)
- Table 4.32: Pfizer' s cancer innovatives profile
- Table 4.33: Pfizer' s cancer innovatives profile (continued)
- Table 4.34: Bristol-Myers Squibb' s cancer innovatives profile
- Table 4.35: Sanofi-Aventis' s cancer innovatives profile
- Table 4.36: Sanofi-Aventis' s cancer innovatives profile (continued)
- Table 4.37: Schering-Plough' s cancer innovatives profile
- Table 4.38: Eli Lilly' s cancer innovatives profile
- Table 4.39: Merck' s cancer innovatives profile
- Table 4.40: Bayer Schering' s cancer innovatives profile
- Table 4.41: Amgen' s cancer innovatives profile
- Table 4.42: GlaxoSmithKline' s cancer innovatives profile
|
 |
